drugset / Trial / NCT00691717

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00691717

Phase 2/3 Completed 201 enrolled Alcon Research
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2008-06
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 24 mg Other
Subject Anecortave Acetate Small molecule 48 mg Other
Subject Anecortave Acetate Small molecule 60 mg Other